108281 20211115135503.0 doi 10.1158/1078-0432.CCR-20-2751 sideral 121002 ART-2020-121002 eng de Miguel, D. (orcid)0000-0002-8486-8514 TRAIL and Cancer Immunotherapy: Take a Walk on the Short Side 2020 Recent work shows that TRAILshort, a membrane-bound short form of TRAIL, is expressed by human cancer cells and protects them from TRAIL-induced cell death. AmAbthat selectively targets TRAILshort enhances cancer susceptibility to TRAIL and increases the efficacy of autologous CD8(+) T cells in ex vivo primary tumors. Access copy available to the general public Unrestricted info:eu-repo/grantAgreement/ES/DGA-FEDER/B29-17R info:eu-repo/grantAgreement/ES/MCIU-AEI/SAF2017-83120-C2-1-R info:eu-repo/semantics/openAccess All rights reserved http://www.europeana.eu/rights/rr-f/ 12.531 2020 ONCOLOGY 18 / 242 = 0.074 2020 Q1 T1 5.426 2020 Oncology 2020 Q1 Cancer Research 2020 Q1 info:eu-repo/semantics/other info:eu-repo/semantics/acceptedVersion Pardo, J. Universidad de Zaragoza (orcid)0000-0003-0154-0730 1011 566 Universidad de Zaragoza Dpto. Microb.Ped.Radio.Sal.Pú. Área Inmunología 26, 21 (2020), 5546-5548 Clin. cancer res. CLINICAL CANCER RESEARCH 1078-0432 864382 http://zaguan.unizar.es/record/108281/files/texto_completo.pdf Postprint 1035894 http://zaguan.unizar.es/record/108281/files/texto_completo.jpg?subformat=icon icon Postprint oai:zaguan.unizar.es:108281 articulos driver 2021-11-15-08:52:15 ARTICLE